BIG
APLS

Brooklyn Investment Group’s Apellis Pharmaceuticals APLS Stock Holding History

Brooklyn Investment Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-241
Closed -$4.17K – 782
2025
Q2 		$4.17K Buy
241
+29
+14% +$537 ﹤0.01% 2550
2025
Q1 		$4.64K Sell
212
-29
-12% -$801 ﹤0.01% 1846
2024
Q4 		$7.69K Buy
241
+214
+793% +$6.43K ﹤0.01% 1080
2024
Q3 		$779 Buy
+27
New +$1K ﹤0.01% 970

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Brooklyn Investment Group's APLS Position: Q3 2025 in Review

Brooklyn Investment Group sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 241 shares — an estimated $4.17K sold.

Brooklyn Investment Group first reported a position in APLS in Q3 2024 and held it in 4 quarters. The position peaked at $7.69K in Q4 2024. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Brooklyn Investment Group reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 241 Apellis Pharmaceuticals shares in Q3 2025, an estimated $4.17K.
  • Brooklyn Investment Group first reported a position in Apellis Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Brooklyn Investment Group's Apellis Pharmaceuticals position peaked at $7.69K in Q4 2024.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.